Neuronetics' Revenue-Linked Debt Changes Depend On At Least $15 Million In Prepayment
Interest, fees and lender expenses come on top of the minimum payment under the conditional agreement with Perceptive.
Neuronetics, which makes the NeuroStar brain-stimulation treatment system, agreed Thursday to revenue-linked borrowing changes that depend on a debt prepayment of at least $15 million, plus interest, fees and expenses. The company described the conditional agreement with Perceptive Credit Holdings IV in an SEC filing Tuesday.
The $15 Million Starting Point
The agreement changes certain revenue covenants—the contractual requirements tied to the company's revenue. To satisfy the prepayment condition, Neuronetics must make an optional payment toward its debt principal of no less than $15 million.
The cash needed to meet that condition extends beyond principal. Neuronetics must also pay accrued interest that remains unpaid, the applicable fee for paying debt early, an amendment fee and the lenders' other costs and expenses.
The revised terms sit within a borrowing relationship that began July 25, 2024, when Neuronetics entered its credit agreement with Perceptive and other lenders. Perceptive acts as the lenders' administrative agent and is the majority lender under the latest agreement.
Systems, Sessions And Greenbrook Clinics
Neuronetics' business combines equipment sales with recurring treatment revenue. It sells NeuroStar systems and treatment sessions primarily to U.S. psychiatrists, and operates 93 Greenbrook centers offering the therapy. Clinic revenue and treatment sessions account for most of its revenue.
NeuroStar provides an office-based, non-invasive treatment called transcranial magnetic stimulation, which stimulates brain areas associated with mood. The system is FDA-cleared for major depressive disorder, obsessive-compulsive disorder in adults, and anxiety symptoms in adults who have depression.
For the year ended December 31, 2025, Neuronetics reported revenue of $149.2 million. It had 658 employees as of that date.
The agreement will automatically terminate unless its conditions are satisfied or waived by November 30, 2026. The revenue-linked changes remain conditional until those requirements are met or waived.
Sources
- 8-K Filing — Neuronetics, Inc. (STIM) — SEC EDGAR